Mucocutaneous herpes simplex virus infections in immunocompromised patients. A model for evaluation of topical antiviral agents.

Abstract

Forty-three immunocompromised patients with progressive cutaneous herpes simplex virus infections were studied in a double-blind, placebo-controlled evaluation of topically applied acyclovir. Patients were randomized and 22 received acyclovir and 21 placebo; medications were applied four times daily for 10 days. Both study populations were balanced for all… (More)

Topics

Cite this paper

@article{Whitley1982MucocutaneousHS, title={Mucocutaneous herpes simplex virus infections in immunocompromised patients. A model for evaluation of topical antiviral agents.}, author={R. S. Whitley and N. Barton and E. Collins and Jennifer Whelchel and Arnold G. Diethelm}, journal={The American journal of medicine}, year={1982}, volume={73 1A}, pages={236-40} }